Aktienanalyse zu Charles River Laboratories International Inc (CRL)CRLCharles River Laboratories International Inc

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes businesses that provide foundational tools that enable its clients to discover new molecules: Research Models and Research Model Services. Its Discovery and Safety Assessment (DSA) segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including the in vitro, in vivo, and in silico studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Charles River Laboratories is a good buy right now due to its strong financial performance, including a recent earnings report showing $3.02 EPS, exceeding expectations of $2.74, and a forward P/E of 22.42, which suggests reasonable valuation compared to growth prospects. Additionally, the stock has shown a year-to-date change of +49.09%, reflecting strong market momentum. The main risk is the negative net income reported in recent quarters, with a net income of -14.84 million in Q1 2026, indicating ongoing challenges that could impact future profitability.

16 analysts cover CRL: 8 rate it Buy, 8 Hold and 0 Sell. The average price target is 226.70.